Lynx Biosciences, Inc. news
At the end of the 19th century, the German scientist Paul Ehrlich began to realize that certain chemicals could have highly specific effects on certain diseases. He began to write about the possibility that a drug could act like a magische kugel—magic bullet—that killed only the organism causing disease, and nothing else.<
In 2009, as a graduate student at the University of Wisconsin-Madison, Chorom Pak was part of a group of researchers working to understand how sensitive patients’ cells were to certain therapies for blood cancers, such as multiple myeloma.
The group, which also included UW-Madison professors
Dr. Chorom Pak, President and CEO, LynxBio was a finalist in the John G. Watson Quick Pitch Competition presented by the Tech Coast Angels and the San Diego Venture Group. She talks about using an advanced approach to diagnosing cancer by using a standard-of-care biopsy to create a living model of a patient`s cancer, including the patient`s own microenvironment, to rapidly identify effective treatment options.
While major cities across the country have built reputations as leaders in the health care market, the Madison area has positioned itself as an emerging center for health innovation. Smaller, yes, but the hub of activity is arguably as robust as other rising markets including Austin, Texas, Salt Lake City and Seattle. Wisconsin’s capital city and surrounding region are home to a network of businesses and organizations, including Epic Systems—the industry leader in elec